Regen BioPharma (RGBP) Equity Average (2016 - 2025)
Historic Equity Average for Regen BioPharma (RGBP) over the last 12 years, with Q4 2025 value amounting to -$6.4 million.
- Regen BioPharma's Equity Average fell 1796.71% to -$6.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.4 million, marking a year-over-year decrease of 1796.71%. This contributed to the annual value of -$5.7 million for FY2025, which is 1140.53% down from last year.
- Per Regen BioPharma's latest filing, its Equity Average stood at -$6.4 million for Q4 2025, which was down 1796.71% from -$6.0 million recorded in Q3 2025.
- Over the past 5 years, Regen BioPharma's Equity Average peaked at -$4.9 million during Q1 2023, and registered a low of -$43.3 million during Q1 2022.
- Its 5-year average for Equity Average is -$10.2 million, with a median of -$5.7 million in 2025.
- Per our database at Business Quant, Regen BioPharma's Equity Average tumbled by 71210.7% in 2022 and then surged by 8865.44% in 2023.
- Regen BioPharma's Equity Average (Quarter) stood at -$11.6 million in 2021, then soared by 44.41% to -$6.5 million in 2022, then grew by 19.93% to -$5.2 million in 2023, then fell by 5.33% to -$5.4 million in 2024, then dropped by 17.97% to -$6.4 million in 2025.
- Its Equity Average stands at -$6.4 million for Q4 2025, versus -$6.0 million for Q3 2025 and -$5.8 million for Q2 2025.